Alternate day fasting for weight loss in normal weight and overweight subjects: a randomized controlled trial

Nutrition Journal

Table 4 Non-lipid coronary heart disease risk factor changes during the 12-week study

	Intervention	Week 1¹	Week 12	P-value²	P-value³	Change⁴	P-value⁵
Systolic BP (mm Hg)	ADF	124 ± 4	117 ± 4	0.02	0.85	-7 ± 2	0.51
	Control	119 ± 3	120 ± 4	0.67		1 ± 3
Diastolic BP (mm Hg)	ADF	78 ± 3	72 ± 2	0.03	0.05	-6 ± 2	0.17
	Control	82 ± 4	84 ± 5	0.28		2 ± 6
Homocysteine (umol/dl)	ADF	9 ± 1	9 ± 1	0.37	0.50	0 ± 1	0.21
	Control	9 ± 1	9 ± 1	0.86		0 ± 1
C-reactive protein (mg/L)	ADF	2 ± 1	1 ± 1	0.29	0.01	-1 ± 1	0.01
	Control	1 ± 1	1 ± 1	0.78		0 ± 1
Adiponectin (ng/ml)	ADF	10728 ± 1251	11401 ± 1197	0.58	0.15	672 ± 1191	<0.01
	Control	11350 ± 1369	10509 ± 1316	0.26		-842 ± 623
Leptin (ng/ml)	ADF	25 ± 4	15 ± 3	0.04	0.55	-10 ± 3	0.03
	Control	22 ± 7	18 ± 6	0.07		-4 ± 3
Resistin (ng/ml)	ADF	18 ± 3	15 ± 4	0.15	0.57	-3 ± 3	0.20
	Control	23 ± 4	21 ± 4	0.26		-2 ± 2

Values reported as mean ± SEM. ADF: Alternate day fasting.
¹Baseline values were not significantly different between intervention groups for any parameter: Independent samples t-test.
²P-value between week 1 and week 12: Paired t-test.
³P-value between groups at week 12: Independent samples t-test.
⁴Absolute change between week 1 and week 12 values.
⁵P-value between groups for absolute change: Independent samples t-test.

ISSN: 1475-2891